Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

odanacatib

- PMLiVE

Novartis and GSK complete oncology and vaccines swap

Follows Swiss company's decision to divest its BRAF and MEK inhibitors to Array BioPharma

- PMLiVE

Amgen’s Kyprolis tops Velcade in myeloma trial

Amgen hoping to topple Takeda’s $2bn a year drug

- PMLiVE

UCB boosted by core medicines growth

Firm’s new chief executive 'excited' by his company’s next batch of medicines

National Institute for Health and Care Excellence NICE logo

NICE backs biosimilars in rheumatoid arthritis guidance

Seven biologic drugs (DMARDs) and two biosimilars recommended

UCB CEO elected to the Ministerial Industry Strategy Group

Jean-Christophe Tellier assumed the role of CEO on January 1

- PMLiVE

Novartis gets OK for panobinostat in myeloma

First HDAC to receive positive FDA review

Eli Lilly HQ

Lilly sets back evacetrapib data deadline

Cholesterol drug trials extended by six months

- PMLiVE

Novartis’ heart failure drug could get FDA nod in summer

Some predicting sales of $5bn within four years for LCZ696

- PMLiVE

Dementia research alliance to fast-track new Alzheimer’s drugs

Will see Alzheimer's Research UK partner with Cambridge, Oxford and UCL universities

- PMLiVE

Personalised cancer medicines showcased in BBC investigation

Panorama looked at cutting-edge science and the new generation of oncology drugs

- PMLiVE

Baxter plans to file long-acting Advate in EU next year

Patients experienced a 95% reduction in bleeds

- PMLiVE

AB Science on track for phase III data in Alzheimer’s this year

Trial of masitinib has passed a futility test

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links